On July 2nd, it was reported by Novartis China that the company's radiopharmaceutical (i.e., "nuclear medicine") production project officially started construction in Haiyan, Zhejiang. This is Novartis' first radioligand therapy production base in China and its second innovative drug production base in China, with an estimated total investment of 600 million RMB. It is reported that, subject to obtaining necessary regulatory approvals and licenses, Novartis China's radiopharmaceutical production project is expected to be completed and put into operation by the end of 2026. Radioligand therapy is an innovative conjugate drug that combines radioactive isotopes with targeted tumor-specific ligands. It can achieve precise and efficient elimination of cancer cells, and due to the moderate radiation distance, it can reduce damage to healthy cells, achieving safe, targeted, and systemic precision treatment of tumors. This therapy aims to redefine the standard treatment for various types of cancer patients. (First Financial)